Table 1.
Enrolled participant characteristics by study site and risk factors*
| Vanderbilt (N=229) |
Marshfield (N=186) |
Combined (N=415) |
||
|---|---|---|---|---|
| Age | Median (IQR) | 57.0 (55.0, 63.0) |
73.0 (69.0,77.8) |
67.0 (57.0, 74.0) |
| Age category | 50-59 | 59% | 0% | 33% |
| 60-69 | 26% | 26% | 26% | |
| 70+ | 15% | 74% | 41% | |
| Sex | Female | 67% | 52% | 60% |
| Male | 33% | 48% | 40% | |
| Race | White | 94% | 100% | 97% |
| Black | 5% | 0% | 3% | |
| Comorbid conditions | Heart disease | 7% | 9% | 7% |
| Lung disease | 10% | 8% | 9% | |
| Immunosuppressed** | 2% | 8% | 4% | |
| VES-13*** | Mean ±SD | 1.1±1.3 | 2.2±2.1 | 1.6±1.8 |
| BMI | Mean ±SD | 28.8± 5.7 | 29.4± 5.4 | 29.0± 5.6 |
| ≥ 30 kg/m2 | 38% | 42% | 40% |
*
includes subjects who completed 3rd study visit, at which time data related to BMI and vulnerability were assessed
**
Immunosuppressed includes history of transplant, immune dysfunction (including HIV), use of systemic steroid medications, receipt of chemotherapy, or use of other immune modulating medications.
***
Higher VES scores is associated with higher vulnerability.